C4J.F Stock Analysis
C4
Uncovered
C4X Discovery Holdings PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm has a portfolio ranging from early-stage novel target opportunities to late-stage drug discovery programs ready for out-licensing to partners. Its Taxonomy3 technology is used to analyze complex genetic datasets to identify and characterize novel drug target candidates. Its Conformetrix technology platform allows the 3D-shapes of free ligands to measure from experimental data. Its pipeline includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor and Oral Orexin-1 Antagonist (C4X 3256/INDV-2000). The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD). MALT1 is a hematological cancer target for Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL).